S-8 1 d320318ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on June 6, 2022

Registration No. 333-    

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Biodesix, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   20-3986492

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification Number)

 

2970 Wilderness Place, Suite 100

Boulder, Colorado

  80301
(Address of Principal Executive Offices)   (Zip Code)

Biodesix, Inc. 2020 Equity Incentive Plan

(Full Title of the Plan)

Scott Hutton

President and Chief Executive Officer

Biodesix, Inc.

2970 Wilderness Place, Suite 100

Boulder, Colorado 80301

(303) 417-0500

(Name, Address and Telephone Number, Including Area Code, of Agent for Service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed by Biodesix, Inc. (the “Registrant”) for the purpose of registering an additional 1,231,586 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) issuable under the Biodesix, Inc. 2020 Equity Incentive Plan (the “2020 Plan”), as a result of the operation of the automatic annual increase provision therein effective January 1, 2022. The shares of the Registrant’s Common Stock previously reserved for issuance under the 2020 Plan were registered on the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on November 2, 2020 (File No. 333-249805) (the “Prior Form S-8”).

This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Form S-8 relates, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Form S-8, to the extent relating to the registration of Common Stock issuable under the 2020 Plan, are incorporated herein by reference and made part of this Registration Statement on Form S-8, except as amended hereby.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

ITEM 3.

INCORPORATION OF DOCUMENTS BY REFERENCE

The Registrant hereby incorporates by reference in this Registration Statement the following documents and information previously filed with the Commission:

 

  (1)

The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Commission on March 14, 2022, including all material incorporated by reference therein;

 

  (2)

The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the Commission on May 11, 2022;

 

  (3)

The Registrant’s Current Reports on Form 8-K, filed with the Commission on January  4, 2022, February  14, 2022, March  7, 2022, April  11, 2022 and May 25, 2022; and

 

  (4)

The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on October 26, 2020, pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report for the purpose of updating such description.

All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).

Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


ITEM 8.

EXHIBITS

 

Exhibit
No.

  

Description

  4.1    Amended and Restated Certificate of Incorporation of Biodesix, Inc. (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-1 (No. 333-249260), filed with the Commission on October 21, 2020).
  4.2    Amended and Restated Bylaws of Biodesix, Inc. (incorporated by reference to Exhibit 3.4 of the Registrant’s Registration Statement on Form S-1 (No. 333-249260), filed with the Commission on October 21, 2020).
  4.3    Biodesix, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant’s Registration Statement on Form S-1 (No. 333-249260), filed with the Commission on October 26, 2020).
  5.1*    Opinion of Sidley Austin LLP with respect to validity of issuance of securities.
23.1*    Consent of Independent Registered Public Accounting Firm.
23.2*    Consent of Sidley Austin LLP (included in Exhibit 5.1).
24.1*    Power of Attorney (included on the signature page of the Registration Statement).
107*    Filing Fee Exhibit.

 

 

*

Each document marked with an asterisk is filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Boulder, Colorado, on the 6th day of June, 2022.

 

Biodesix, Inc.
By:  

/s/ Scott Hutton

  Scott Hutton
  President and Chief Executive Officer
(Principal Executive Officer)

POWER OF ATTORNEY AND SIGNATURES

Each of the undersigned officers and directors of Biodesix, Inc. does hereby severally constitute and appoint Scott Hutton and Robin Harper Cowie, and each of them acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

SIGNATURE

  

TITLE

 

DATE

/s/ Scott Hutton

   President and Chief Executive Officer and Director   June 6, 2022
Scott Hutton    (Principal Executive Officer)  

/s/ Robin Harper Cowie

   Chief Financial Officer and Treasurer   June 6, 2022
Robin Harper Cowie    (Principal Financial Officer)  

/s/ Ryan Siurek

   Chief Accounting Officer   June 6, 2022
Ryan Siurek    (Principal Accounting Officer)  

/s/ John Patience

   Director   June 6, 2022
John Patience     

/s/ Jean Franchi

   Director   June 6, 2022
Jean Franchi     

/s/ Jon Faiz Kayyem, Ph.D.

   Director   June 6, 2022
Jon Faiz Kayyem, Ph.D.     

/s/ Hany Massarany

   Director   June 6, 2022
Hany Massarany     

/s/ Jack Schuler

   Director   June 6, 2022
Jack Schuler     


SIGNATURE

  

TITLE

 

DATE

/s/ Matthew Strobeck, Ph.D.

   Director   June 6, 2022
Matthew Strobeck, Ph.D.     

/s/ Charles Watts, M.D.

   Director   June 6, 2022
Charles Watts, M.D.